ASH News Daily - Sunday, December 11, 2011 - (Page A-5)
Sunday, December 11, 2011
ASH/EHA
Raising Awareness for Global Vaccines
By david gaRcia, Md, and
ShaRi ghanny, Md
that 33 million people are living
with HIV, the worst affected region
being sub-Saharan Africa. According
to the WHO, in 2005, just over
14 percent of all new HIV infections
occurred in children under 15 years
of age. Although great advances
have been made in the treatment of
HIV infection with the use of com-
I
n 1981, the first cases of AIDS
began to emerge in the United
States. Currently, it is estimated
bination anti-retroviral therapy,
the virus’s elegant design and its
ability to evade the host’s immune
system has been the focus of scientific
research for years. This and
other global health vaccines will be
the focus of this afternoon’s ASH/
EHA Joint Symposium.
In 2003, the Global HIV Vaccine
Enterprise was created as a worldwide
collaborative effort that includes
more than 30 independent
organizations committed to the research
and development of a preventive
HIV vaccine. The founda-
tion of the Enterprise stems from
its Scientific Strategic Plan, a framework
upon which the Enterprise
Council could share, expand, and
execute its vision. The Plan includes
reports from five working groups,
highlighting the collaborative and
multi-disciplinary approach needed
for this endeavor: Immunogens and
Antigen Processing; Host Genetics
and HIV Diversity; Novel Approaches
to HIV Vaccine Research
& Development; Bridging the Gaps
between Fundamental, Preclinical,
and Clinical Research; and Young
and Early Career Investigators. In
2010, the Plan was updated to prioritize
objectives required to integrate
pre-clinical and clinical research.
When asked about his thoughts
on the progress and challenges of
vaccines for global health, former
Executive Director of the Global HIV
Vaccine Enterprise and main speaker
at this afternoon’s symposium, Dr.
Alan Bernstein responded:
“These are exciting times in global
health. Vaccines are unquestionably
»» GLOBAL VACCINES Page A-16
ASH NEWS DAILY
Page A–5
®
Locate the mutation.
Stay one step ahead of CML resistance.
Register at booth #503 or visit
www.CMLResponseProject.com.
©2011 ARIAD Pharmaceuticals, Inc. All rights reserved.
5343311
REGISTER AT
BOOTH
#503
21425 ARIA ASH Program Ad_Mv1.indd 1
10/14/11 11:50 AM
Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011
ASH News Daily - Sunday, December 11, 2011
https://www.nxtbookmedia.com